Pediatrix Medical Group, Inc. (NYSE:MD) Receives Average Rating of “Hold” from Analysts

Pediatrix Medical Group, Inc. (NYSE:MD) has received a consensus rating of “Hold” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $24.8333.

A number of equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $25.00 target price on shares of Pediatrix Medical Group in a report on Wednesday, August 5th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a report on Friday, May 8th. UBS Group raised their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Jefferies Financial Group reiterated a “buy” rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a report on Monday, April 20th. Finally, Truist Financial boosted their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th.

Pediatrix Medical Group Stock Performance

Shares of Pediatrix Medical Group stock opened at $26.51 on Thursday. The business has a 50-day simple moving average of $25.33 and a 200 day simple moving average of $22.72. Pediatrix Medical Group has a one year low of $14.75 and a one year high of $27.94. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.32 and a quick ratio of 1.32. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of 12.68 and a beta of 0.66.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04. The firm had revenue of $487.78 million during the quarter, compared to analysts’ expectations of $478.49 million. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.53 earnings per share. On average, research analysts anticipate that Pediatrix Medical Group will post 2.12 earnings per share for the current fiscal year.

Institutional Trading of Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in shares of Pediatrix Medical Group in the second quarter valued at approximately $347,383,000. Wasatch Advisors LP bought a new stake in Pediatrix Medical Group during the first quarter worth $43,861,000. Bank of New York Mellon Corp purchased a new stake in Pediatrix Medical Group in the 2nd quarter valued at $14,297,000. Rockefeller Capital Management L.P. raised its position in Pediatrix Medical Group by 814.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 594,351 shares of the company’s stock valued at $12,713,000 after buying an additional 529,367 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in Pediatrix Medical Group by 175.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after acquiring an additional 474,186 shares in the last quarter. 97.71% of the stock is owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.